Trilaciclib Improves Chemo’s Effectiveness Against Small Cell Lung Cancer, Study Finds
News
Adding the CDK4/6 inhibitor trilaciclib to chemotherapy can generate significant benefits for patients with advanced small cell lung cancer (SCLC), according to a Phase 1b/2a clinical trial. Trilaciclib preserved blood stem ... Read more